07:00 , May 2, 2011 |  BC Week In Review  |  Clinical News

V419: Phase III started

Merck and sanofi-aventis' Sanofi Pasteur S.A. vaccines unit began an open-label, international Phase III trial in about 1,440 infants to evaluate 0.5 mL intramuscular V419. Subjects will receive V419 at 2, 4, 6 and 15...
07:00 , Mar 17, 2008 |  BC Week In Review  |  Clinical News

Daptacel regulatory update

FDA approved an sBLA for use of Daptacel diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine as a fifth consecutive dose for children aged 4 through 6 years of age. Daptacel, which was approved...
07:00 , May 20, 2002 |  BC Week In Review  |  Clinical News

Daptacel diphtheria and tetanus toxoids and acellular pertussis regulatory update

The FDA granted marketing approval to AVE's Aventis Pasteur unit (Swiftwater, Penn.) for its DTaP vaccine to immunize children against diptheria, tetanus and pertussis. Aventis S.A. (AVE), Strasbourg, France   Product: Daptacel diphtheria and tetanus...
07:00 , May 15, 2002 |  BC Extra  |  Company News

FDA approves Aventis pertussis vaccine

The FDA granted marketing approval to AVE's Aventis Pasteur unit (Swiftwater, Penn.) for its Daptacel diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine....